Wintermute is Now Recruiting Patients for the ZosterEase Phase Ib Clinical Trial. Read more here.
Company CEO Dr. Tom Rau to present novel nano-micelle solution for combating biowarfare threats, traumatic wound infections, and drug-resistant pathogens
Wintermute Biomedical is set to make a significant impact at the upcoming Military Health System Research Symposium this August, where CEO Dr. Tom Rau will present the company's revolutionary antimicrobial technology. This breakthrough comes after 12 years of intensive research and development, promising a game-changing solution for both military and civilian healthcare.
The company's innovative suite of fatty acid-based nano-micelle antimicrobials has demonstrated potent activity against critical biowarfare threats, including pathogens that cause plague (Y. pestis), tularemia (F. tularensis), anthrax, and melioidosis (B. pseudomallei). More impressively, these compounds have shown effectiveness against a wide range of multi-drug resistant pathogens (P. aeruginosa, A. baumannii, and C. auris) that pose significant challenges in clinical settings.
What sets Wintermute's GS series compounds apart is their versatility and practicality. These water-soluble, thermostable agents boast an impressive shelf life and can be administered as foam, gel, or powder. Their ability to maintain antimicrobial efficacy even after water evaporation opens exciting possibilities for long-term protection.
"We envision battlefield soldiers carrying GS-1 powder to apply directly to traumatic wounds, potentially revolutionizing infection control in combat situations," says Dr. Rau. "In hospitals, our technology could significantly reduce surgical site infections and combat nosocomial pathogens."
The presentation will highlight recent promising preclinical results in a mouse model of burn wound infection, further underscoring the potential of this technology to transform wound care and infection control strategies.
As antibiotic resistance continues to pose a global threat, Wintermute Biomedical's innovative approach offers a beacon of hope. The upcoming symposium presentation represents a crucial step in bringing this groundbreaking technology to those who need it most – from the battlefield to the hospital ward.
Details of the talk:
Location: Gaylord Palms Resort and Convention Center, Kissimmee FL.
Date and time: Wed 28 August 1300-1500.
Breakout Session: Strategies for Mitigating the Development of Post-traumatic Wound Infections with Multi-drug Resistant Organisms across the Continuum of Care
Title: Novel ammonium carboxylate salts as broad-spectrum biodefense antimicrobials for wound, skin, and surface decontamination.